FDA J&J booster vote updates: Panel unanimously endorses extra shots; FDA pressed on speed of review

This was CNBC's live blog covering the FDA's Vaccines and Related Biological Products Advisory Committee meeting Friday to debate and vote on booster shots for Johnson & Johnson's Covid vaccine. This blog will be updated throughout the day as the news breaks.

The Food and Drug Administration's key vaccine advisory panel met Friday to discuss and vote on Johnson & Johnson's Covid-19 booster shots and to debate mix-and-match vaccines. The group unanimously recommended extra shots of J&J for everyone 18 and older who originally received the jabs.

On Thursday, the Vaccines and Related Biological Products Advisory Committee recommended the use of Moderna's booster shots to people 65 and over and other at-risk groups.

Ahead of the meeting, the FDA staff told the committee there may be a benefit to administering a second dose of J&J's vaccine two months after the first shot. They also said one J&J dose was consistently less effective than the mRNA vaccines made by Pfizer and Moderna in clinical trials and in real-world studies.